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Abstract
Background: Staphylococcus epidermidis (SE) is a nosocomial pathogen that causes catheter-associated bacteremia in the
immunocompromised, including those at the extremes of age, motivating study of host clearance mechanisms. SE-derived
soluble components engage TLR2; but additional signaling pathways have also been implicated, and TLR2 can play complex,
at times detrimental, roles in host defense against other Staphylococcal spp. The role of TLR2 in responses of primary blood
leukocytes to live SE and in clearance of SE bacteremia, the most common clinical manifestation of SE infection, is unknown.
Methodology/Principal Findings: We studied TLR2-mediated recognition of live clinical SE strain 1457 employing TLR2-
transfected cells, neutralizing anti-TLR antibodies and TLR2-deficient mice. TLR2 mediated SE-induced cytokine production
in human embryonic kidney cells, human whole blood and murine primary macrophages, in part via recognition of a soluble
TLR2 agonist. After i.v. challenge with SE, early (1 h) cytokine/chemokine production and subsequent clearance of
bacteremia (24–48 h) were markedly impaired in TLR2-deficient mice.
Conclusions/Significance: TLR2 mediates recognition of live SE and clearance of SE bacteremia in vivo.
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Introduction
Staphylococci spp. are frequent causes of nosocomial infection [1,2].
Coagulase-negative staphylococci, especially S. epidermidis (SE) are
ubiquitous skin commensals and a major cause of nosocomial
bacteremia, particularly in immunocompromised patients and
those with implantable medical devices [3]. The ability of
Staphylococcus spp. to cause disease has been ascribed to immune
evasion, including avoidance of opsonophagocytosis [4]. SE lacks
genome islands found in S. aureus (SA) encoding pathogenesis
factors, likely contributing to its lesser virulence [5]. Nevertheless,
SE is a frequent cause of bacteremia, especially at the extremes of
age, resulting in significant morbidity and mortality [6]. SE
attaches to foreign material, interacts with the host extracellular
matrix and elaborates biofilm, reducing deposition of comple-
ment/IgG, susceptibility to host antimicrobial peptides and
neutrophil-mediated killing [3,7,8].
Characterization of the Toll-like receptor (TLR) system
[9,10,11,12] has paved the way for studies implicating TLR2 in
recognition of Gram-positive bacteria [9,10,13]. However, additional
recognition pathways of Gram-positive bacteria include b-integrins
[14,15], lectins [16], CD36 [17], and nucleotide oligomerization
domain proteins 1 and 2 (NOD1 and -2) [18], members of the NOD-
like receptor (NLR) family of cytosolic sensors [19]. SA-derived factors
activate NODs1 and -2 and the NLRP3 inflammasome [18,20] and
NOD2 contributes to cutaneous defense against live SA in vivo [21].
There is evidence both in favor and against a role for TLR2 in
host defense against several Gram-positive bacteria, including SA
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[18,22,23,24]. The complexity of the data may relate to distinct
routes of infection in murine models- e.g., i.p. vs. i.v. [22,25],
differences in bacterial preparations (e.g., live vs. killed) and
inoculum size, and differences in innate immunity between mice
and humans [26]. Live SA subverts TLR2 to inhibit superoxide
production by murine macrophages thereby prolonging survival of
SA in phagosomes [23]. Thus the roles of TLR2 in innate
responses to SA are context dependent, and may include
detrimental roles in infection outcome.
SE also engages the innate immune system [6]. Killed SE
preparations induce cytokine production from human peripheral
blood mononuclear cells in vitro [27,28,29,30], and fractions
containing SE-derived phenol-soluble modulin peptides (PSMs)
induce cytokine production in TLR2-transfected HEK cells and
primary murine cells [31,32,33,34]. SE surface polysaccharide
intercellular adhesin activates human astrocytoma cells via TLR2
[35]. In contrast, SE-derived peptidoglycan (PG) activates human
monocytic THP-1 cells via both TLR2 (polymeric PG) and NOD2
(monomeric PG) [36].
Although SE-derived factors can activate human cultured cells
via TLR2 and NOD2, their relative contribution to responses of
primary leukocytes to live SE in vitro or clearance of SE bacteremia
in vivo- experimental settings that may most closely mimic clinical
infection- are undefined. As bacteremia is the major clinical
manifestation of SE infection, characterizing bloodstream clear-
ance mechanisms is a priority. We therefore investigated the
interaction of live SE with TLR2, studying both human and
murine cells in vitro and intravenous infection of mice in vivo,
thereby avoiding potential limitations inherent to study of killed
bacteria, isolated bacteria-derived factors, or analyses relying on a
single mammalian species [26,37]. We demonstrate for the first
time that live SE, which elaborates a TLR2-activating soluble
factor (SE-S), can activate primary cells via human and murine
TLR2 in vitro and that TLR2 substantially and selectively
contributes to clearance of SE bacteremia in vivo.
Methods
Ethics statement
Blood was collected from healthy donors after written informed
consent in accordance with the institutional review board-
approved study protocols of Children’s hospital Boston (X07-05-
0223). All animal protocols were approved by the Animal Care
and Use Committee of Children’s Hospital Boston (08-11-1261R).
Bacteria
Wild-type (WT) SE strain 1457, obtained from a patient with an
infected central venous catheter [38], was grown to mid-log phase
in Brain Heart Infusion Broth (PathWest, Perth, Australia),
collected by centrifugation and resuspended in pyrogen-free
PBS. Lipopolysaccharide (LPS) contamination of SE preparations
was excluded by Limulus amebocyte lysate assay (Associates of
Cape Cod, East Falmouth, MA) and lack of response by TLR4-
transfected HEK293 cells (Invivogen, San Diego, CA). For study
of the SE-derived soluble factor (SE-S), SE were grown overnight
in trypticase soy broth (TSB), centrifuged at 29006g at 4uC for
5 min and the supernatant filtered (0.2 mm) and stored at 220uC
until use.
TLR agonists
TLR agonists used in this study included fibroblast-stimulating
lipopeptide-1 (FSL-1, TLR2/6, 1 mg/ml; InvivoGen), ultra-pure
LPS from Salmonella minnesota devoid of TLR2-stimulating activity
(TLR4; 100 ng/ml; List Biological Laboratories, Campbell, CA).
Whole Blood
Blood was collected either in sodium heparin tubes (Vacutainer;
Becton Dickinson or Greiner, Kremsmu¨nster, Austria) and tested
whole, or mixed 1:1 with RPMI 1640 (Gibco, Life Technology,
Paisley, Scotland) prior to culture in polypropylene tubes or in
round-bottom 96-well plates (Corning Incorporated) at 37uC/5%
CO2. Culture supernatants were harvested and stored at 220uC.
Antibody blocking
Heparinized whole blood was incubated with 10 mg/ml
neutralizing, azide- and antibiotic-free, IgA mAbs to human
TLR2 or TLR4 (Invivogen) for 30 min prior to addition of FSL-1
(1 mg/ml), LPS (100 ng/ml) or SE (106/ml). After 4 h, culture
supernatants were harvested and stored at 220uC prior to IL-6
ELISA. To exclude effects on bacterial viability, blood was plated
onto blood agar plates and CFUs enumerated, after overnight
incubation (37uC/5% CO2). For blocking SE-S, whole blood was
incubated with neutralizing azide-free rat polyclonal Abs against
human TLR2, TLR4, TLR6 or isotype control (Invivogen) for
30 min prior to addition of stimulus. After 18 h, culture
supernatants were harvested and stored at 220uC.
TLR-transfected human embryonic kidney cells
Stable cell lines of human embryonic kidney (HEK)-293 cells
transfected with TLR2 or TLR4/MD2 were cultured in
supplemented DMEM containing 10% heat-inactivated FCS
and 10 mg/ml ciprofloxacin [39]. After antibiotic removal, cells
were stimulated with SE (106–108 bacteria/ml) or pure TLR
agonists for 24 h (5%CO2, 37uC), and cell culture supernatants
harvested for storage at 220uC.
Cytokine Assays
Human cytokines were measured by time resolved fluorometry
(TRF; IL-6), commercial ELISA (IL-8 and IL-6; eBioscience, San
Diego, CA) per manufacturers’ instructions, using Maxisorp flat-
bottom plates (Nunc, Roskilde, Denmark) [40] or by employing
multi-analyte flurometric beads (Milliplex, Millipore) on a
Luminex xMAP system (Luminex Corp., Austin, TX) using
BeadView Multiplex Software v.1 (Upstate Cell Signaling
Solutions, Temecula, CA).
Mice
TLR2-deficient (Jackson laboratories; Bar Harbor, ME) and
C57BL/6 WT (Taconic; Hudson, NY) female mice were
confirmed by genotype (PCR) and phenotype (impaired peritoneal
macrophage response to FSL-1 with preserved response to LPS)
and matched for age.
Bacteremia Model
Adult mice 7–12 weeks old were injected i.v. with 108 SE. Blood
was collected by submandibular bleed at 1, 4, 24 and 48 h post-
infection. For cytokine analysis, blood was diluted (5 volumes
RPMI) and plasma collected (12006g at 4uC; 5 min) and stored at
220uC.
Primary peritoneal macrophages
Murine macrophages were obtained from the peritoneal cavity
of mice 3 days after i.p. thioglycollate injection. Adherent cells
were maintained in DMEM supplemented with 10% FCS and
ciprofloxacin (10 mg/ml) at 5% CO2/37uC. Following ciproflox-
acin removal by washing with PBS, cells were stimulated with SE
(104–108/ml) for 4 h and cell culture supernatants stored at
220uC.
TLR2 and S. epidermidis
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Trans-well assays
SE were added to the upper chamber of a 0.4 mm trans-well
system in a 24 well plate (Corning Costar; Acton, MA) in DMEM
with 10% FCS for 4 h. There were no live SE found in lower
chamber. Cell culture supernatants were harvested and stored at
220uC prior to cytokine measurement.
Murine cytokines
Murine cytokines were determined by ELISA (TNF and IL-6;
R&D Systems; Minneapolis, MN) or by employing multi-analyte
flurometric beads (Milliplex, Millipore) on a Luminex xMAP
system (Luminex Corp., Austin, TX) using BeadView Multiplex
Software v.1 (Upstate Cell Signaling Solutions, Temecula, CA).
Statistical Analyses
Statistical analyses employed Graphpad Prism v5.0 for
Macintosh (GraphPad, La Jolla, CA). Unless stated otherwise in
the figure legend, comparisons between 2 groups were by the
Mann-Whitney U test and those between .2 groups were by the
Figure 1. Transfection of human embryonic kidney cells with
TLR2 confers responsiveness to live SE. Transfection of HEK293
cells with TLR2 enhanced SE-induced IL-8 production after 24 h of
stimulation (n = 3).
doi:10.1371/journal.pone.0010111.g001
Figure 2. Neutralizing anti-TLR2 antibody inhibit SE-induced cytokine production in human blood. Blocking anti-TLR IgA Abs were
added to human whole blood (10 mg/ml) 30 min prior to stimulation with SE (106/ml) for 4 h and extracellular IL-6 measured by ELISA. (A) Anti-TLR2
Ab selectively inhibited FSL-, but not LPS-induced IL-6 production (representative of four similar experiments). (B) Composite analysis of inhibition
expressed as %IL-6 production relative to control (no Ab); n = 4; (C) Selective inhibition of SE-induced IL-6 by anti-TLR2, but not anti-TLR4 Ab
(representative of 4 similar experiments). (D) Composite analysis of inhibition expressed as %IL-6 production, relative to control (no Ab). 1 sample-t-
test vs. 100% (n = 4); * p,0.05.
doi:10.1371/journal.pone.0010111.g002
TLR2 and S. epidermidis
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Kruskal-Wallis test with Dunn’s post-test. P-values ,0.05 were
considered statistically significant.
Results
Transfection of TLR2 into HEK cells confers
responsiveness to SE
We first confirmed that live SE could engage TLR2 to induce
cytokine production by assessing TLR2-transfected HEK cells.
TLR2-transfected HEK cells demonstrated dramatically increased
IL-8 production in response to SE (Fig. 1), indicating that live SE
engages TLR2. In contrast, transfection of HEK cells with TLR4/
MD-2 did not enhance SE-induced IL-8 production (data not
shown).
SE-induced cytokine production is inhibited by blocking
TLR2 in whole blood
To assess the potential role of TLR2 in SE-induced innate
immune responses in human blood, we investigated the effect of
blocking anti-TLR Abs on SE-induced IL-6 production in human
whole blood (Fig. 2). Pre-incubation of human whole blood with
neutralizing anti-TLR2 and TLR4 Abs (10 mg/ml) inhibited
cytokine responses to FSL-1 and LPS, respectively (Fig 2A & B).
Pre-incubation of human whole blood with anti-TLR2 Ab
inhibited SE-induced IL-6 production by .50%, whereas pre-
incubation with anti-TLR4 had no effect (Fig. 2C & D).
Impaired SE-induced TNF production in TLR22/2murine
peritoneal macrophages
We subsequently measured cytokine responses to SE in
peritoneal macrophages derived from wild-type and TLR2-
deficient mice. As expected, TLR2-deficient peritoneal macro-
phages demonstrated marked impairment in TNF production in
response to FSL-1 (TLR2/6) but equivalent response to LPS
(TLR4) (Fig. 3A). TLR2-deficient macrophages demonstrated
marked impairment in SE-induced TNF, particularly at lower
concentrations of SE tested (104–106 CFU/ml; Fig. 3B). In
contrast, TNF responses to high concentrations of SE (107–108)
were largely TLR2-independent (Fig. 3B). Four hours after
infection with 105 LSE, TLR2-deficient macrophages also
demonstrated diminished production of IL-6, as well as the
chemokines CXCL1 and CXCL2 (Fig. 3C & D).
SE secretes a soluble TLR2 agonist
We next assessed whether the TLR2 agonist activity of SE may
be released as a soluble factor. In trans-well experiments in which
Figure 3. Impaired SE-induced cytokine production from primary TLR22/2 murine peritoneal macrophages. Primary murine
peritoneal macrophages (pmacs) from WT and TLR2-deficient C57BL/6 mice were stimulated with SE for 4 h. (A) Selectively impaired bacterial
lipopeptide FSL-1-induced cytokine response in TLR2-deficient pmacs, with normal responses to LPS (TLR4). (B) TLR2-deficient pmacs demonstrated
markedly impaired TNF production to low concentrations (104–106 bacteria/ml) of SE (n = 3–9). * p,0.05. (C) SE-induced production of IL-6, CXCL1,
and CXCL2 was lower in TLR2-deficient pmacs (representative of 3 similar experiments). (D) Composite analysis demonstrating % cytokine production
of TLR2-deficient pmacs relative to WT (n = 3, one-sample t-test versus 100%). *p,0.05.
doi:10.1371/journal.pone.0010111.g003
TLR2 and S. epidermidis
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SE were placed in the upper chamber, wild-type murine
macrophages in the lower chamber produced TNF, CXCL1
and CXCL2 suggesting the secretion of a soluble factor that could
traverse the semi-permeable membrane (Fig. 4A). This SE-derived
secreted factor (SE-S) was highly TLR2-dependent as responses of
TLR2-deficient macrophages were dramatically impaired (Fig. 4A,
Figure 4. A soluble factor from SE activates cytokine production in a TLR2-dependent manner. (A) SE in a trans-well upper chamber
induced cytokine production in WT, but not TLR2-deficient murine peritoneal macrophages (pmacs; representative of 3 similar experiments); (B)
Composite trans-well analysis expressed as %IL-6 production in TLR2-deficient vs. WT pmacs (n = 3, 1-sample t-test vs. 100%); (C) Filtered
supernatants of stationary phase SE contain a soluble factor (SE-S) which induced diminished cytokine/chemokine production from TLR2-deficient
pmacs (representative of 3 similar experiments); (D) composite analysis of SE-S-induced cytokine/chemokine production in TLR2-deficient vs. WT
pmacs (n = 3, one-sample t-test versus 100%). (E) SE-S induced concentration-dependent IL-6 production in human whole blood, (F) neutralizing anti-
TLR2 polyclonal Abs, but not anti-TLR4 polyclonal Abs, blunted SE-S-induced IL-6 in human whole blood. * p,0.05.
doi:10.1371/journal.pone.0010111.g004
TLR2 and S. epidermidis
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and composite analysis in Fig. 4B). Accordingly, TLR2-deficient
pmacs demonstrated impaired SE-S-induced cytokine and che-
mokine production (Fig. 4C & D). SE-S also induced IL-6
production in human whole blood in a concentration-dependent
manner (Fig. 4E), an activity that was inhibited by neutralizing
anti-TLR2 Abs (Fig. 4F).
SE-induced cytokine production in vivo is mediated via
TLR2
To test whether TLR2 contributes to SE-induced cytokine
production in peripheral blood in vivo, we injected SE i.v. to wild-
type or TLR2-deficient mice then measured cytokine production
by collecting blood plasma at 1 h (Fig. 5). TLR2-deficient mice
demonstrated markedly diminished production of IL-6, IL-10, G-
CSF, CXCL1 and CXCL2 in vivo (Fig. 5A), that was significant
upon composite analysis (Fig. 5B).
TLR2 mediates clearance of SE bacteremia in vivo
To assess the role of TLR2 in clearance of SE, C57BL/6 wild-
type or TLR2-deficient mice were injected i.v. with SE (108 CFU)
prior to collection of blood for analysis. TLR2-deficient mice
demonstrated impaired clearance of SE bacteremia, with dramat-
ically and significantly higher peripheral blood concentrations of
SE at 24 and 48 h (Fig. 6).
Discussion
We have demonstrated for the first time the importance of
TLR2 in recognition of live SE as measured by whole blood
cytokine production and highlight a selective role of TLR2 in
clearance of SE bacteremia. TLR2 mediated SE-induced cytokine
production in TLR2-transfected HEK cells, human whole blood,
and murine primary peritoneal macrophages. TLR2-deficient
mice injected intravenously with SE demonstrated reduced early
(1 h) cytokine/chemokine induction and selectively and markedly
impaired subsequent clearance of bacteremia at 24–48 h.
SE releases an as yet unidentified soluble factor (SE-S) that
activates both human and murine cells via TLR2 (Fig. 4C & D).
We speculate that release of SE-S may contribute to responses to
SE in vivo. Indeed, our evidence that TLR2 plays a prominent role
in recognition of, and responses to, SE is consistent with the ability
of SE-derived surface components to induce inflammation [41],
including TLR2 agonists such as PSM [31,33], surface polysac-
charide intercellular adhesin [35] and peptidoglycan [36].
Whether the SE-S activity detected in our present study reflects
these or other molecules [42] will be the subject of future work.
Impaired production of cytokines in response to intravenous SE
was associated with impaired clearance of bacteremia, suggesting
that TLR2-mediated cytokine production may contribute to
clearance of SE in vivo. In contrast, Raby et al recently reported
that after i.p. challenge with SE, administration of inhibitory
soluble TLR2 (sTLR2) reduced peritoneal PMN infiltration, but
did not reduce bacterial clearance from the peritoneal cavity [32].
Our distinct results likely reflect different routes of bacterial
challenge and different approaches to TLR2 inhibition, with
genetic ablation providing a more definitive approach. SE engages
TLR2, but at high bacterial concentrations can activate primary
murine macrophages via a TLR2-independent pathway, indicat-
ing engagement of additional pattern recognition pathways,
possibly including NLRs and the inflammasome [36,37,43].
Figure 5. SE-induced cytokine production is TLR2-dependent in vivo. Female C57BL/6 WT or TLR2-deficient mice were injected intravenously
with 108 CFU SE prior to collection of peripheral blood at 1 h for measurement of cytokines/chemokines by using multi-analyte flurometric beads as
described in Methods. (A) SE-induced production of cytokines/chemokines is lower in TLR2-deficient mice (representative of 3 similar experiments).
(B) Composite analysis demonstrating % cytokine production of TLR2-deficient mice relative to WT (n = 3, one-sample t-test versus 100%). *p,0.05.
doi:10.1371/journal.pone.0010111.g005
Figure 6. TLR2-deficient mice demonstrate impaired clearance
of SE bacteremia. Female C57BL/6 WT or TLR2-deficient mice were
injected i.v. with 108 CFU of SE prior to collection of peripheral blood at
1, 4, 24 or 48 h for measurement of CFUs by plating serial dilutions
(n = 4–9); *p,0.05.
doi:10.1371/journal.pone.0010111.g006
TLR2 and S. epidermidis
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Multiple aspects of our studies of live SE are novel: a) SE (and
SE-S) activates cytokine production via TLR2 in human whole
blood, b) TLR2 is particularly important in detecting low
concentrations of SE in primary murine macrophages, whereas
high concentrations of SE can activate these cells in a TLR2-
independent manner, c) TLR2 mediates early (1 h) cytokine
production after i.v. challenge with SE in vivo and d) TLR2 plays a
crucial and selective role in mediating subsequent clearance of SE
bacteremia at 24–48 h in vivo. We speculate that in TLR2-deficient
animals, reduced production of early (1 h) plasma cytokines,
including IL-6, impairs subsequent clearance of staphylococci, as
has also been suggested in humans with neutralizing anti-IL-6
auto-antibodies [44].
In conclusion, our study is the first to demonstrate the
importance of TLR2 in recognition of live SE in whole blood, a
key site of SE infection, in vitro and in vivo. We have demonstrated a
selective role of TLR2 in clearance of SE bacteremia, the most
common, harmful and costly clinical manifestation of SE infection
[3,4]. Our study may inform efforts to develop novel adjunctive
approaches to prevent and/or treat SE infection [45]. Novel
TLR2 antagonists in biopharmaceutical development may reduce
SE-induced inflammation, but may also impair clearance of SE
bacteremia. Conversely, enhancing TLR2-mediated host defense
may hasten clearance of SE bacteremia; consistent with protection
against bacteremia afforded by hypermorphic alleles of TIRAP, a
signaling molecule downstream of TLR2 [46]. Future studies
should define the roles of TLR2 in susceptibility of immunocom-
promised populations, particularly those at the extremes of age, to
SE bacteremia [6].
Acknowledgments
We thank Drs. Michael Wessels, Raif Geha, Richard Malley, Anthony Keil
and Peter Campbell for mentorship and intellectual input. David Atlas,
Cristina Farrar (Dept. Clinical Microbiology PathWest, Princess Margaret
Hospital for Children), and the research assistants of the School of
Paediatrics and Child Health Vaccine Trials Group provided expert
technical assistance.
Author Contributions
Conceived and designed the experiments: TS MRPC AJC PR DB OL.
Performed the experiments: TS MRPC LSB LCG. Analyzed the data: TS
MRPC LSB LCG. Contributed reagents/materials/analysis tools: DTG
MO OL. Wrote the paper: TS MRPC OL.
References
1. Karchmer AW, Bayer AS (2008) Methicillin-resistant Staphylococcus aureus: an
evolving clinical challenge. Clin Infect Dis 46 Suppl 5: S342–343.
2. Venkatesh MP, Placencia F, Weisman LE (2006) Coagulase-negative staphylo-
coccal infections in the neonate and child: an update. Semin Pediatr Infect Dis
17: 120–127.
3. Otto M (2008) Staphylococcal biofilms. Curr Top Microbiol Immunol 322:
207–228.
4. Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3:
948–958.
5. Gill SR, Fouts DE, Archer GL, Mongodin EF, Deboy RT, et al. (2005) Insights
on evolution of virulence and resistance from the complete genome analysis of
an early methicillin-resistant Staphylococcus aureus strain and a biofilm-
producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol
187: 2426–2438.
6. Strunk T, Richmond P, Simmer K, Currie A, Levy O, et al. (2007) Neonatal
immune responses to coagulase-negative staphylococci. Curr Opin Infect Dis 20:
370–375.
7. Kristian SA, Birkenstock TA, Sauder U, Mack D, Gotz F, et al. (2008) Biofilm
formation induces C3a release and protects Staphylococcus epidermidis from
IgG and complement deposition and from neutrophil-dependent killing. J Infect
Dis 197: 1028–1035.
8. von Eiff C, Peters G, Heilmann C (2002) Pathogenesis of infections due to
coagulase-negative staphylococci. Lancet Infect Dis 2: 677–685.
9. Wetzler LM (2003) The role of Toll-like receptor 2 in microbial disease and
immunity. Vaccine 21 Suppl 2: S55–60.
10. Royet J, Dziarski R (2007) Peptidoglycan recognition proteins: pleiotropic
sensors and effectors of antimicrobial defences. Nat Rev Microbiol 5: 264–277.
11. Akira S (2006) TLR signaling. Curr Top Microbiol Immunol 311: 1–16.
12. O’Neill LA (2008) When signaling pathways collide: positive and negative
regulation of toll-like receptor signal transduction. Immunity 29: 12–20.
13. Henneke P, Dramsi S, Mancuso G, Chraibi K, Pellegrini E, et al. (2008)
Lipoproteins are critical TLR2 activating toxins in group B streptococcal sepsis.
J Immunol 180: 6149–6158.
14. Cuzzola M, Mancuso G, Beninati C, Biondo C, Genovese F, et al. (2000) Beta 2
integrins are involved in cytokine responses to whole Gram-positive bacteria.
Journal of Immunology 164: 5871–5876.
15. Levy O, Jean-Jacques R, Cywes C, Sisson R, Zarember KA, et al. (2003) Critical
role of the complement system in Group B streptococcus-induced tumor necrosis
factor alpha release. Infect Immun 71: 6344–6353.
16. Albanyan EA, Edwards MS (2000) Lectin site interaction with capsular
polysaccharide mediates nonimmune phagocytosis of type III group B
streptococci. Infect Immun 68: 5794–5802.
17. Stuart LM, Deng J, Silver JM, Takahashi K, Tseng AA, et al. (2005) Response to
Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the
COOH-terminal cytoplasmic domain. J Cell Biol 170: 477–485.
18. Kapetanovic R, Nahori MA, Balloy V, Fitting C, Philpott DJ, et al. (2007)
Contribution of phagocytosis and intracellular sensing for cytokine production
by Staphylococcus aureus-activated macrophages. Infect Immun 75: 830–837.
19. Shaw MH, Reimer T, Kim YG, Nunez G (2008) NOD-like receptors (NLRs):
bona fide intracellular microbial sensors. Curr Opin Immunol 20: 377–382.
20. Munoz-Planillo R, Franchi L, Miller LS, Nunez G (2009) A critical role for
hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced
activation of the Nlrp3 inflammasome. J Immunol 183: 3942–3948.
21. Hruz P, Zinkernagel AS, Jenikova G, Botwin GJ, Hugot JP, et al. (2009) NOD2
contributes to cutaneous defense against Staphylococcus aureus through alpha-
toxin-dependent innate immune activation. Proc Natl Acad Sci U S A 106:
12873–12878.
22. Skerrett SJ, Liggitt HD, Hajjar AM, Wilson CB (2004) Cutting edge: myeloid
differentiation factor 88 is essential for pulmonary host defense against
Pseudomonas aeruginosa but not Staphylococcus aureus. J Immunol 172:
3377–3381.
23. Watanabe I, Ichiki M, Shiratsuchi A, Nakanishi Y (2007) TLR2-mediated
survival of Staphylococcus aureus in macrophages: a novel bacterial strategy
against host innate immunity. J Immunol 178: 4917–4925.
24. Knuefermann P, Sakata Y, Baker JS, Huang CH, Sekiguchi K, et al. (2004) Toll-
like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction
and cytokine production in the heart. Circulation 110: 3693–3698.
25. Takeuchi O, Hoshino K, Akira S (2000) Cutting edge: TLR2-deficient and
MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection.
Journal of Immunology 165: 5392–5396.
26. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse
and human immunology. J Immunol 172: 2731–2738.
27. Hartel C, Osthues I, Rupp J, Haase B, Roder K, et al. (2008) Characterisation of
the host inflammatory response to Staphylococcus epidermidis in neonatal whole
blood. Arch Dis Child Fetal Neonatal Ed 93: F140–145.
28. Robinson WA, Entringer MA, Bolin RW, Stonington OG, Jr. (1977) Bacterial
stimulation and granulocyte inhibition of granulopoietic factor production.
N Engl J Med 297: 1129–1134.
29. Stuyt RJ, Kim SH, Reznikov LL, Fantuzzi G, Novick D, et al. (2003) Regulation
of Staphylococcus epidermidis-induced IFN-gamma in whole human blood: the
role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine 21: 65–73.
30. Megyeri K, Mandi Y, Degre M, Rosztoczy I (2002) Induction of cytokine
production by different Staphylococcal strains. Cytokine 19: 206–212.
31. Hajjar AM, O’Mahony DS, Ozinsky A, Underhill DM, Aderem A, et al. (2001)
Cutting edge: functional interactions between toll-like receptor (TLR) 2 and
TLR1 or TLR6 in response to phenol-soluble modulin. Journal of Immunology
166: 15–19.
32. Raby AC, Le Bouder E, Colmont C, Davies J, Richards P, et al. (2009) Soluble
TLR2 reduces inflammation without compromising bacterial clearance by
disrupting TLR2 triggering. J Immunol 183: 506–517.
33. Equils O, Schito ML, Karahashi H, Madak Z, Yarali A, et al. (2003) Toll-like
receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat
trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells:
implications of simultaneous activation of TLRs on HIV replication. J Immunol
170: 5159–5164.
34. Otto M, O’Mahoney DS, Guina T, Klebanoff SJ (2004) Activity of
Staphylococcus epidermidis phenol-soluble modulin peptides expressed in
Staphylococcus carnosus. J Infect Dis 190: 748–755.
35. Stevens NT, Sadovskaya I, Jabbouri S, Sattar T, O’Gara JP, et al. (2008)
Staphylococcus epidermidis Polysaccharide Intercellular Adhesin induces IL-8
TLR2 and S. epidermidis
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10111
expression in human astrocytes via a mechanism involving TLR2. Cell
Microbiol.
36. Natsuka M, Uehara A, Shuhua Y, Echigo S, Takada H (2008) A polymer-type
water-soluble peptidoglycan exhibited both Toll-like receptor 2- and NOD2-
agonistic activities, resulting in synergistic activation of human monocytic cells.
Innate Immun 14: 298–308.
37. Gekara NO, Dietrich N, Lyszkiewicz M, Lienenklaus S, Weiss S (2009) Signals
triggered by a bacterial pore-forming toxin contribute to toll-like receptor
redundancy in gram-positive bacterial recognition. J Infect Dis 199: 124–133.
38. Mack D, Siemssen N, Laufs R (1992) Parallel induction by glucose of adherence
and a polysaccharide antigen specific for plastic-adherent Staphylococcus
epidermidis: evidence for functional relation to intercellular adhesion. Infect
Immun 60: 2048–2057.
39. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, et al. (2002)
Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the
toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the
initiation of signal transduction. Journal of Biological Chemistry 277:
47834–47843.
40. Rowe J, Heaton T, Kusel M, Suriyaarachchi D, Serralha M, et al. (2004) High
IFN-gamma production by CD8+ T cells and early sensitization among infants
at high risk of atopy. J Allergy Clin Immunol 113: 710–716.
41. McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, et al.
(2003) Interplay between IFN-gamma and IL-6 signaling governs neutrophil
trafficking and apoptosis during acute inflammation. J Clin Invest 112: 598–607.
42. McCurdy JD, Olynych TJ, Maher LH, Marshall JS (2003) Cutting edge: distinct
Toll-like receptor 2 activators selectively induce different classes of mediator
production from human mast cells. J Immunol 170: 1625–1629.
43. Cole LE, Santiago A, Barry E, Kang TJ, Shirey KA, et al. (2008) Macrophage
proinflammatory response to Francisella tularensis live vaccine strain requires
coordination of multiple signaling pathways. J Immunol 180: 6885–6891.
44. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, et al. (2008) Recurrent
staphylococcal cellulitis and subcutaneous abscesses in a child with autoanti-
bodies against IL-6. J Immunol 180: 647–654.
45. Schaffer AC, Lee JC (2009) Staphylococcal vaccines and immunotherapies.
Infect Dis Clin North Am 23: 153–171.
46. Ferwerda B, Alonso S, Banahan K, McCall MB, Giamarellos-Bourboulis EJ,
et al. (2009) Functional and genetic evidence that the Mal/TIRAP allele variant
180L has been selected by providing protection against septic shock. Proc Natl
Acad Sci U S A 106: 10272–10277.
TLR2 and S. epidermidis
PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10111
